Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D08PMW
|
||||
| Former ID |
DIB009901
|
||||
| Drug Name |
BMS-223131
|
||||
| Synonyms |
4-(5-Chloro-2-hydroxyphenyl)-3-(2-hydroxyethyl)-6-(trifluoromethyl)quinolin-2(1H)-one
|
||||
| Indication | Erectile dysfunction [ICD9: 302.72, 607.84; ICD10:F52.2, N48.4] | Phase 2 | [527426] | ||
| Target and Pathway | |||||
| Target(s) | Maxi K potassium channel | Target Info | Modulator | [527426] | |
| Reactome | cGMP effects | ||||
| WikiPathways | Potassium Channels | ||||
| Platelet homeostasis | |||||
| References | |||||
| Ref 527426 | Effect of 4-(5-chloro-2-hydroxyphenyl)-3-(2-hydroxyethyl)-6-(trifluoromethyl)-quinolin-2(1H)-one (BMS-223131), a novel opener of large conductance Ca2+-activated K+ (maxi-K) channels on normal and stress-aggravated colonic motility and visceral nociception. J Pharmacol Exp Ther. 2005 May;313(2):840-7. Epub 2005 Feb 8. | ||||
| Ref 527426 | Effect of 4-(5-chloro-2-hydroxyphenyl)-3-(2-hydroxyethyl)-6-(trifluoromethyl)-quinolin-2(1H)-one (BMS-223131), a novel opener of large conductance Ca2+-activated K+ (maxi-K) channels on normal and stress-aggravated colonic motility and visceral nociception. J Pharmacol Exp Ther. 2005 May;313(2):840-7. Epub 2005 Feb 8. | ||||
If you find any error in data or bug in web service, please kindly report it to Dr. Tang and Dr. Mou.